Placeholder Banner

BIO Welcomes Seven New Board Members

February 12, 2016
BIO elected seven new members to its Board of Directors, voted upon at this year’s Board Meetings, held this week in New York City.

The following individuals were elected to the Health Section Governing Board:

  • Christopher Boerner, President and Head of the U.S. Commercial Business, BMS

  • Mark Alles, President and Chief Operating Officer, Celgene

  • Gary Zieziula, President and Managing Director, EMD Serono

  • Elizabeth Lewis, Chief Counsel and Chief Compliance Officer, Takeda Pharmaceuticals

  • Jean-Christophe Tellier, Chief Executive Officer, UCB


The following individuals were elected to the Emerging Companies Section Governing Board

  • Jeremy Levin, CEO and Chairman of the Board of Directors, Ovid Therapeutics

  • Perry Karsen, Chairman of the Board, Jounce Therapeutics


“These individuals are highly respected within the industry and we are thrilled to welcome them to BIO’s Board of Directors. Their expertise and insights on how to propel this industry forward will benefit our policy and advocacy efforts, as well as advancing our business development support for companies both large and small,” said Jim Greenwood, the President and CEO of BIO.